AGN Allergan plc Ordinary Shares

-2  -1%
Previous Close 237.83
Open 237.83
Price To book 1.12
Market Cap 79.16B
Shares 335,224,000
Volume 2,261,037
Short Ratio 2.69
Av. Daily Volume 3,051,060

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Approval announced March 20, 2017.
Correction of moderate to severe facial wrinkles and folds
Phase 3 trial to be initiated 2H 2017.
Cortisol Analog
Dry Eye disease
Phase 2 top-line data due 2H 2017.
Brimo DDS
Atrophic Age-related macular degeneration (AMD)
Phase 2b data due 2018.
Crohn's disease
Phase 3 enrollment to be completed 2H 2017.
Androgenic Alopecia
Phase 2 top-line data released April 5, 2017 - primary endpoint missed. Phase 3 planned.
Phase 3 data due 2018.
Major depressive disorder (MDD)
Phase 2b trial to be initiated 2H 2017.
RORγt agonist
sNDA filing acceptance announced March 8, 2017. PDUFA date not noted.
Schizophrenia/ Negative symptoms
Phase 3 data released March 27 2017 - primary endpoints met. NDA filing due 2H 2017.
Severe acne vulgaris
Phase 2b top-line data due 2018.
Prophylaxis (migraine)
Phase 3 initiated July 2016. Data due 2018.
Acute (migraine)
Phase 3 to be initiated 2H 2017.
Diabetic Gastroparesis
Phase 3 initiated October 2016. Data due early 2019.
Major depressive disorder (MDD)
Phase 3 data released January 18, 2017 - endpoints met. NDA filing due 2H 2017.
ESMYA (Venus II)
Uterine Fibroids
Phase 3 to be initiated 2H 2017.
Cenicriviroc (CVC)
Nonalcoholic steatohepatitis (NASH)
Phase 3 trial to be initiated 2H 2017.
Diabetic macular edema (DME)
Phase 3 data due 2018.
Age-related macular degeneration (AMD)
sNDA acceptance announced October 11, 2016. Approval announced January 30, 2017.
AVYCAZ (ceftazidime and avibactam)
Complicated Urinary Tract Infections (cUTI)
Approved January 19, 2017.
Oxymetazoline HCl cream 1.0%
Facial Erythema (Redness) Associated with Rosacea
sNDA approval announced January 26, 2017.
Linaclotide 72 mcg dose for use in the treatment of adults
Chronic idiopathic constipation (CIC)
sNDA accepted January 4, 2017. PDUFA estimate September 4, 2017.
Prevention of pregnancy
BLA filed November 15, 2016. PDUFA estimate September 15, 2017.
ABP 215
Biosimilar candidate to Avastin (bevacizumab)

Latest News

  1. Trump Executive Order Could Revive Allergan-Pfizer Merger
  2. Charlie Munger: Loading Up on Leverage
  3. Top Analyst Upgrades and Downgrades: Costco, Domino’s Pizza, Fortinet, Verizon, Yum Brands and More
  4. Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL
  5. Allergan Announces 13 Presentations on Chronic Migraine, Upper and Lower Limb Spasticity, Cervical Dystonia and Alzheimer's Disease at the American Academy of Neurology Meeting in Boston
  6. Chapel Hill company partners with Allergan
  7. Allergan Partners with TARGET PharmaSolutions to Advance NASH Research
  8. Allergan (AGN) Collaborates with Novartis to Treat NASH
  9. ($$) Investors bet on Incyte drug success
  10. Allergan, Argentum settle patent dispute over eye drug Restasis
  11. Allergan Expands Leading Research & Development NASH Program with Novartis Clinical Collaboration
  12. A Healthcare Pick That's Moderately Shielded From Upheaval
  13. Why Charlie Munger Hates Value Investing
  14. Allergan and Ironwood Launch Campaign Designed to Empower the Nearly 64 Million Americans Estimated to Suffer from IBS and CIC to Talk About Bowel Health(1-5)
  15. The Real Trump Trade May Be Gold: Cramer's 'Mad Money' Recap (Tuesday 4/11/17)
  16. Cramer Remix: Why a slew of IPOs might not be a good thin...
  17. Cramer's charts show these biotechs ignoring their 'polit...
  18. Allergan Launches Frames of Mind, Encouraging People Living with Migraine to Share Common Experiences Through Art
  19. How Did Allergan Perform in 1Q17?
  20. Allergan Receives 2017 ENERGY STAR® Partner of the Year - Sustained Excellence Award from U.S. Environmental Protection Agency